The publication aims to compare urosepsis rates in people with type 2 diabetes treated using SGLT2i inhibitors with DPP4i inhibitors in a real‐world setting.
Citation
Anat Fisher MD, Michael Fralick MD, Kristian B. Filion PhD, Sophie Dell’Aniello MSc, Antonios Douros MD, Éric Tremblay BPharm, Baiju R. Shah MD, Paul E. Ronksley PhD, Silvia Alessi-Severini PhD, Nianping Hu PhD, Shawn C. Bugden PharmD, Pierre Ernst MD, Lisa M. Lix PhD, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. First published: 08 May 2020 https://doi.org/10.1111/dom.14082